July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Early improvement of central retinal thickness as a predictor for anatomical outcome and response in the treatment of diabetic macular edema with intravitreal injections of anti-VEGF
Author Affiliations & Notes
  • Johannes Schiefelbein
    Ludwig-Maximilians-University, Department of Ophthalmology, Munich, Germany
  • Michael Müller
    Ludwig-Maximilians-University, Department of Ophthalmology, Munich, Germany
  • Christoph Kern
    Ludwig-Maximilians-University, Department of Ophthalmology, Munich, Germany
  • Tina Herold
    Ludwig-Maximilians-University, Department of Ophthalmology, Munich, Germany
  • Raffael Liegl
    Ludwig-Maximilians-University, Department of Ophthalmology, Munich, Germany
  • Dawn A Sim
    Moorfields Eye Hospital , London, United Kingdom
  • Maximilian Weiß
    Ludwig-Maximilians-University, Department of Ophthalmology, Munich, Germany
  • Siegfried Priglinger
    Ludwig-Maximilians-University, Department of Ophthalmology, Munich, Germany
  • Karsten Ulrich Kortuem
    Ludwig-Maximilians-University, Department of Ophthalmology, Munich, Germany
    Moorfields Eye Hospital , London, United Kingdom
  • Footnotes
    Commercial Relationships   Johannes Schiefelbein, None; Michael Müller, None; Christoph Kern, None; Tina Herold, None; Raffael Liegl, None; Dawn Sim, None; Maximilian Weiß, None; Siegfried Priglinger, None; Karsten Kortuem, Alcon (R), Allergan (R), Bayer (F), Bayer (R), Big Picture (C), Google Deepmind (C), Novartis (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3602. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Johannes Schiefelbein, Michael Müller, Christoph Kern, Tina Herold, Raffael Liegl, Dawn A Sim, Maximilian Weiß, Siegfried Priglinger, Karsten Ulrich Kortuem; Early improvement of central retinal thickness as a predictor for anatomical outcome and response in the treatment of diabetic macular edema with intravitreal injections of anti-VEGF. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3602.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of this study was to investigate relations between early improvement of central retinal thickness (CRT) and further therapy response in the treatment of diabetic macular edema (DME) with intravitreal injections of anti-VEGF.

Methods : We analyzed real life data from the database of the Dept. of Ophthalmology of Ludwig-Maximilians-University, Munich.
57 patients and 68 eyes with center-involving DME were treated with intravitreal anti-VEGF therapy in our institution. All patient eyes started with a CRT ≥ 400 μm at baseline and were reviewed over a follow-up period of at least 360 days. All patients received at least 3 injections of anti-VEGF medication.
We analyzed the SD-OCT (Spectralis, Heidelberg Engineering, Germany) and measured the visual acuity (VA) before and during the treatment. An anti-VEGF responder was defined by a reduction of more than 10% of the CRT after 90 days of treatment (57 eyes). A poor responder was defined by a reduction of 10% or less of the CRT after 90 days (11 eyes).

Results : The mean VA and CRT at baseline were 0.61 (± 0.37) logMar (responder: 0.62 (±0.38) logMar; poor responder: 0.55 (±0.29) logMar) and 570.74 (± 143.06) μm (responder: 573.51(± 146.60) μm; poor responder: 556.36 (± 128.47) μm).
On average, the VA changed by -0.097 (± 0.282) logMar after 90 days and by -0.085 (± 0.355) logMar after 360 days while the CRT changed by -190.29 (± 181.56) μm after 90 days and by -185.59 (± 189.52) μm after 360 days. We spotted a significant difference in the CRT after 90 days of treatment (p=0.001) between responder 342.98 (±108.72) μm and poor responder 574.55 (±149.09) μm. Moreover, the Mann-Whitney-U-Test showed significant differences in the change of the CRT after 90 days (p=0.001) and after 360 days (p=0.048) of treatment. In contrast, no significant differences in age, number of injections after 90 days and 360 days, VA and CRT at baseline, VA and CRT after 360 days could be found.

Conclusions : On average, responder showed a higher improvement in VA and in CRT after 360 days in comparison to poor responder, which in contrast did not show an improvement of the VA after 360 days. Early CRT reduction after 90 days may help predict which DME patients will respond more beneficially in further anti-VEGF pharmacotherapy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×